SB 202190
p38 MAP kinase inhibitor / Potent and selective p38 MAP kinase inhibitor acting at the ATP site1. Selectively inhibits the p38α and β isoforms (IC50= 50 and 100 nM for SAPK2a/p38 and SAPK2b/p38β2 respectively)2. Effectively blocks LPS-induced gene expression in monocytes3. Induces apoptosis4. Cell permeable.
Biochemicals & reagents
152121-30-7
1) Young et al. (1997), Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site; J. Biol. Chem., 272 12116 / 2) Davies et al. (2000), Specificity and mechanism of action of some commonly used protein kinase inhibitors; Biochem. J., 351 95 3) Manthey et al. (1998), SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRBAs in monocytes; J. Leukoc. Biol., 64 409 / 4) Nemoto et al. (1998), Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase; J. Biol. Chem., 273 16415
-20°C
TARGET: Kinase -- PATHWAY: Apoptosis inducer; MAPK; Transcription; Apoptosis inhibitors; Autophagy; Cytokine -- RESEARCH AREA: Cell death; Stem cells -- DISEASE AREA: Infectious disease